BIOLARGO, INC.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
The following documents are filed as a part of this report:
1.Financial Statements. The consolidated financial statements required to be filed in this report are listed on the Index to Financial Statements immediately preceding the financial statements.
2.Financial Statement Schedules. Separate financial statement schedules have been omitted either because they are not applicable or because the required information is included in the consolidated financial statements or the notes thereto.
3.Exhibits. See the Exhibit Index for a list of the exhibits being filed or furnished with or incorporated by reference into this report.
Exhibit Index
| Incorporated by Reference Herein | |||
| Exhibit Number | Exhibit Description | Form | File Date |
| 3.2 | Amended and Restated Certificate of Incorporation for BioLargo, Inc. filed March 16, 2007 | Form 10-KSB | 5/4/2007 |
| 3.3 | Certificate of Amendment to Certificate of Incorporation, filed May 25, 2018 | Pos Am | 6/22/2018 |
| 3.4 | Certificate of Amendment to Certificate of Incorporation, filed August 30, 2022 | Form 10-Q | 11/14/2022 |
| 4.1 | BioLargo, Inc. 2007 Equity Incentive Plan | Form 10-QSB | 11/19/2007 |
| 4.2 | Amendment No. 1 to BioLargo 2007 Equity Incentive Plan | Def 14C (Exhibit A) | 5/2/2011 |
| 4.4 | 2018 Equity Incentive Plan | Form S-8 | 6/22/2018 |
| 4.5 | Stock Option Award Agreement under 2018 Equity Incentive Plan | Form S-8 | 6/22/2018 |
| 4.6 | Notice of Stock Option Grant under 2018 Equity Incentive Plan | Form S-8 | 6/22/2018 |
| 4.7 | Restricted Stock Unit Award Agreement under 2018 Equity Incentive Plan | Form S-8 | 6/22/2018 |
| 4.8 | Notice of Restricted Stock Unit Award under 2018 Equity Incentive Plan | Form S-8 | 6/22/2018 |
| 4.9 | Revolving Line of Credit Agreement dated June 30, 2020, between Clyra Medical and Vernal Bay | Form 8-K | 7/7/2020 |
| 4.10 | Security Agreement dated June 30, 2020, between Clyra Medical and Vernal Bay | Form 8-K | 7/7/2020 |
| 4.11 | Revolving Line of Credit Note issued by Clyra Medical to Vernal Bay on June 30, 2020 | Form 8-K | 7/7/2020 |
| 4.12 | Warrant issued in BioLargo Unit Offerings | Form 10-Q | 8/14/2020 |
| 10.3 | Consulting Agreement dated December 30, 2015 with Beach House Consulting LLC | Form 8-K | 1/6/2016 |
| 10.4 | Commercial Office Lease Agreement for Westminster California | Form 8-K | 8/24/2016 |
| 10.5† | Employment Agreement with Dennis P. Calvert dated May 2, 2017. | Form 8-K | 5/4/2017 |
| 10.6† | Lock-Up Agreement with Dennis P. Calvert dated April 30, 2017 | Form 8-K | 5/4/2017 |
| 10.7† | Lock-Up Agreement with Dennis P. Calvert dated May 2, 2017. | Form 8-K | 5/4/2017 |
| 10.8 | Commercial Office Lease Agreement for Oak Ridge Tennessee | Form 8-K | 9/8/2017 |
| 10.9 | Form of Employment Agreement for Engineering subsidiary employee (BLEST) | Form 8-K | 9/8/2017 |
| 10.10 | Form of Option issued to founding employees of Engineering subsidiary (BLEST) | Form 8-K | 9/8/2017 |
| 10.11† | Joseph L. Provenzano Employment Agreement dated May 28, 2019 | Form 8-K | 6/24/2019 |
| 10.12 | Purchase Agreement, dated as of March 30, 2020 by and between BioLargo, Inc. and Lincoln Park Capital Fund, LLC. | Form 8-K | 3/31/2020 |
| 10.13 | Amendment dated June 30, 2020 to Consulting Agreement dated December 30, 2015 between Clyra Medical and Beach House Consulting LLC | Form 8-K | 7/7/2020 |
| 10.14† | 2022 Engagement Extension Agreement with CFO | Form 8-K | 3/24/2022 |
| 10.15 | Registration Rights Agreement, dated as of December 13, 2022, by and between BioLargo, Inc. and Lincoln Park Capital Fund, LLC | Form 8-K | 12/19/2022 |
| 10.16 | Purchase Agreement, dated as of December 13, 2022, by and between BioLargo, Inc. and Lincoln Park Capital Fund, LLC. | Form 8-K | 12/19/2022 |
| 10.18† | 2023 Engagement Extension Agreement with CFO | Form 8-K | 3/27/2023 |
| 10.19 | Form of Share Exchange Agreement between BioLargo, Inc., and purchasers of Clyra Medical Series A Preferred Stock | Form 10-Q | 5/17/2023 |
| 10.20 | Form of Share Exchange Agreement between BioLargo, Inc., and purchasers of BioLargo Energy Technologies, Inc. common stock | Form 10-Q | 5/17/2023 |
| 10.21† | 2024 Engagement Extension Agreement with CFO | Form 10-Q | 8/15/2024 |
| 21.1* | List of Subsidiaries of the Registrant | filed herewith | |
| 23.1* | Consent of Hacker Johnson & Smith PA | filed herewith | |
| 31.1* | Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13(a)-14 and 15(d)-14 under the Securities Exchange Act of 1934 | filed herewith | |
| 31.2* | Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13(a)-14 and 15(d)-14 under the Securities Exchange Act of 1934 | filed herewith | |
| 32* | Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350. | filed herewith | |
| 101.INS** | Inline XBRL Instance | ||
| 101.SCH** | Inline XBRL Taxonomy Extension Schema | ||
| 101.CAL** | Inline XBRL Taxonomy Extension Calculation | ||
| 101.DEF** | Inline XBRL Taxonomy Extension Definition | ||
| 101.LAB** | Inline XBRL Taxonomy Extension Labels | ||
| 101.PRE** | Inline XBRL Taxonomy Extension Presentation | ||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101) | ||
- Filed herewith
** Furnished herewith
† Management contract or compensatory plan, contract or arrangement
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.